العلاج غير الجراحي لسرطان الخلايا القاعدية منخفض الخطورة عندما لا يحقق الاستئصال الجراحي هوامش سليمة

References

• Topical therapies and destructive approaches can be considered in patients with low-risk superficial BCC.
• Photodynamic therapy is an effective treatment for superficial and low-risk nodular BCCs.
• Topical or destructive (blind) treatments can be considered for low-risk superficial and nodular BCC in patients declining surgery or not amenable to surgery.
• Curettage ± electrodesiccation and cryotherapy may be alternative treatments for small, low-risk BCC.
• Topical 5% imiquimod should be used in the treatment of primary superficial and small nodular BCC.
• Imiquimod is an immune response modifier indicated for the treatment of sBCC in immunocompetent adults, applied once daily, five times per week for 6 weeks.
• Topical 5% 5-FU should be used for the treatment of superficial BCC.
• The 5% formulation of the antimetabolite 5-FU is licenced for the treatment of sBCC with two applications daily for 3–6 weeks.
• Photodynamic therapy using 5-ALA or MAL in combination with red light should be used for the treatment of superficial and low-risk nodular BCC.
• Treatment consists of two sessions 1 week apart.
• For nodular BCC treated by MAL-PDT, 91% were clinically clear at 3 months, with a sustained lesion clearance response rate of 76% after 5 years of follow-up.